AbCellera Results Presentation Deck

Q1 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 10 Capital allocation to maximize long-term value while minimizing risk. Forward integration to expand the capabilities of our engine, including manufacturing, regulatory, and clinical activities Develop technology to unlock new target classes and modalities, including, T-cell engagers, and GPCRs and ion channels Build the portfolio by advancing high- quality programs and partnerships

View entire presentation